Business Model Breakdown
How Lantheus Holdings Inc Makes Money
LNTH
Market Cap
$5.4B
Annual Revenue
$407M
Profit Margin
15.2%
Employees
808
The Short Version
Lantheus Holdings Inc. is a radiopharmaceutical company that develops, manufactures, and commercializes innovative diagnostic and therapeutic products for medical imaging and targeted oncology treatments. They primarily generate revenue by selling specialized radiopharmaceuticals, such as PYLARIFY for prostate cancer imaging, to hospitals, imaging centers, and healthcare providers. Their business model focuses on leveraging proprietary compounds and regulatory expertise to address unmet medical needs in areas like cardiology, oncology, and neurology, with an increasing strategic pivot towards therapeutic agents.
Where the Revenue Comes From
PYLARIFY sales (diagnostic radiopharmaceutical for prostate cancer) (~60-70% of revenue in recent periods, though declining)
Other diagnostic radiopharmaceuticals (e.g., DEFINTY, TechneLite)
Emerging therapeutic radioligand pipeline products (e.g., PNT2003, future contribution)
Who buys: Hospitals, imaging centers, nuclear pharmacies, clinics, and other healthcare providers specializing in cardiology, oncology, and other medical imaging fields.
Why It Works (Competitive Advantages)
- ✔Proprietary radiopharmaceutical portfolio and intellectual property for established products like PYLARIFY.
- ✔Established distribution network and prescriber base in diagnostic imaging.
- ✔Early-mover advantage and leadership in specific PSMA PET imaging segments.
Economic Moat: Narrow (Intangible Assets/IP (patents, regulatory approvals for specialized radiopharmaceuticals), Switching Costs (for healthcare providers adopting new diagnostic agents and integrating into workflows))
What Our Analysis Says
DVR Score as of April 23, 2026
Lantheus Holdings is a profitable, well-managed company with a strong position in radiopharmaceutical diagnostics. However, achieving a 10x valuation ($54B) from its current $5.4B market cap within 3-5 years is an exceptionally high hurdle. The recently reported Q4 2025 earnings highlight a material deceleration: FY2026 revenue guidance implies a decline from FY2025, and flagship PYLARIFY sales dropped 9.7% YoY. While the pipeline, especially PNT2003, offers long-term therapeutic potential, the near-term growth trajectory is challenged. This makes the exponential growth required for a 10x return within the specified timeframe highly improbable, even with a solid financial foundation and proven leadership.